New probiotic fights inflammatory bowel diseasesFebruary 1st, 2011 - 2:46 pm ICT by ANI
Washington, Feb 1 (ANI): Northwestern Medicine researchers say that a genetically tweaked version of a common probiotic found in yogurt and cheese may be an effective therapy for inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.
It may also prove to be useful in colon cancer, another disease triggered by inflammation.
The researchers deleted a gene in the probiotic Lactobacillus acidophilus and fed the new form to mice with two different models of colitis. After 13 days of treatment, the novel probiotic strain nearly eliminated colon inflammation in the mice and halted progression of their disease by 95 percent.
“This opens brand new avenues to treat various autoimmune diseases of the gut, including inflammatory bowel disease and colon cancer, all which can be triggered by imbalanced inflammatory immune responses,” said Mansour Mohamadzadeh, associate professor of medicine at Northwestern University Feinberg School of Medicine and lead investigator of the study. He also is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
While the origin of these bowel diseases is not known, Crohn’s disease and ulcerative colitis are two chronically relapsing diseases in which sufferers have an ongoing tissue inflammation that alters the functioning of the intestine.
“Such gene targeting in a probiotic bacteria such as Lactobacillus acidophilus offers the possibility of a safe, drug-free treatment in the near future,” he said.
In the study, the modified Lactobacillus acidophilus entered the gut, which is akin to a battlefield of friendly fire with immune cells attacking the intestine. The Lactobacillus acidophilus acted as the gut’s peacekeeping force, calming the overstimulated immune cells.
The probiotic restored intestinal peace by mobilizing messenger immune cells, called dendritic cells. The dendritic cells, in turn, enhanced the production of other functional immune cells, regulatory T-cells that rebalanced intestinal and systemic inflammation.
“They essentially calm everything down and restore it to normal,” Mohamadzadeh explained. The next step will be a clinical trial with the new form of Lactobacillus acidophilus.
The study has been published in the Proceedings of the National Academy of Sciences. (ANI)
- New probiotic can treat irritable bowels - Feb 01, 2011
- Prebiotic helps lower colon cancer risk: study - May 04, 2012
- Low-calorie diet tied to bowel disease deaths - Mar 21, 2012
- Protein that contributes to ulcerative colitis revealed - Apr 02, 2011
- Common gut bug 'fights Salmonella-induced inflammatory bowel disease' - Nov 02, 2010
- How swallowing worms can heal ulcerative colitis - Dec 02, 2010
- 29 genome regions linked to common form of inflammatory bowel disease - Feb 07, 2011
- Probiotic bacteria effectively treat colitis in mice - Oct 26, 2009
- New drug target for inflammatory bowel disease found - Apr 01, 2011
- Gut bug may hold key to inflammatory bowel disease treatment - Jan 20, 2010
- Sound health depends on minority microbes - Aug 03, 2011
- Probiotic bacteria 'could help in Crohn's disease therapy' - Apr 01, 2011
- Nanotechnology could help smuggle drugs into the gut - Nov 05, 2010
- Novel discovery may offer improved therapies for inflammatory bowel disease - Jun 03, 2009
- Vitamin D receptor plays pivotal role amid "gut flora - Jul 08, 2010
Tags: acidophilus, autoimmune diseases, colon cancer, comprehensive cancer center, crohn s disease, dendritic cells, effective therapy, feinberg school of medicine, immune cells, immune responses, inflammatory bowel disease, inflammatory bowel diseases, lurie comprehensive cancer center, northwestern university feinberg school of medicine, peacekeeping force, probiotic bacteria, robert h lurie, tissue inflammation, tweaked version, ulcerative colitis